# FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Canonical URL: https://biopharmsignal.com/news/ARQT/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-ps-597a9084
Ticker: ARQT
Company: Arcutis Biotherapeutics
Source: Arcutis Biotherapeutics
Published: 2026-06-29 23:07 EST
Original Source URL: https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-03-treatment-0
## Summary

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of use Seventh FDA approval for ZORYVE in

## Article Body
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of use Seventh FDA approval for ZORYVE in
## Recent Company News
- 2026-07-02 20:00 EST — [Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-6524924c) — Source: Arcutis Biotherapeutics
- 2026-06-30 13:16 EST — [Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications](https://biopharmsignal.com/news/ARQT/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-indiv-1503fca8) — Source: Arcutis Biotherapeutics
- 2026-06-29 23:07 EST — [FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2](https://biopharmsignal.com/news/ARQT/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-ps-597a9084) — Source: Arcutis Biotherapeutics
- 2026-06-25 13:46 EST — [New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology](https://biopharmsignal.com/news/ARQT/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology) — Source: Arcutis Biotherapeutics
- 2026-06-25 13:46 EST — [Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ARQT/arcutis-management-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Arcutis Biotherapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)